Nektar Therapeutics NKTRreported a loss of 60 cents per share for the first quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of 52 cents and the year-ago figure of 42 cents due to higher R&D costs.
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться